Option Care Health, Inc. (NASDAQ:OPCH) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Option Care Health, Inc. (NASDAQ:OPCH - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the eight brokerages that are covering the company, MarketBeat Ratings reports. Two analysts have rated the stock with a hold rating and six have given a buy rating to the company. The average 12-month target price among brokerages that have covered the stock in the last year is $33.75.

Several equities research analysts have recently commented on the stock. Barrington Research restated an "outperform" rating and issued a $38.00 target price on shares of Option Care Health in a research note on Monday, April 21st. Jefferies Financial Group upgraded Option Care Health from a "hold" rating to a "buy" rating and increased their price target for the stock from $26.00 to $35.00 in a research report on Thursday, January 23rd. JMP Securities reissued a "market outperform" rating and issued a $36.00 price objective on shares of Option Care Health in a research note on Tuesday, April 22nd. Bank of America raised Option Care Health from a "neutral" rating to a "buy" rating and lifted their price target for the company from $26.00 to $33.00 in a report on Monday, January 13th. Finally, JPMorgan Chase & Co. upped their target price on shares of Option Care Health from $40.00 to $41.00 and gave the stock an "overweight" rating in a research report on Thursday, March 6th.

Insider Activity at Option Care Health

In related news, insider Michael Bavaro sold 30,996 shares of the company's stock in a transaction on Friday, February 28th. The shares were sold at an average price of $33.26, for a total value of $1,030,926.96. Following the completion of the sale, the insider now owns 44,974 shares in the company, valued at $1,495,835.24. This represents a 40.80 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 0.64% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. JPMorgan Chase & Co. lifted its stake in Option Care Health by 29.6% in the fourth quarter. JPMorgan Chase & Co. now owns 1,511,403 shares of the company's stock valued at $35,065,000 after buying an additional 344,875 shares in the last quarter. Graypoint LLC bought a new stake in Option Care Health during the 4th quarter worth about $1,161,000. Charles Schwab Investment Management Inc. grew its holdings in shares of Option Care Health by 6.2% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 2,510,131 shares of the company's stock valued at $58,235,000 after acquiring an additional 147,054 shares in the last quarter. Global Alpha Capital Management Ltd. boosted its position in Option Care Health by 38.1% during the fourth quarter. Global Alpha Capital Management Ltd. now owns 68,810 shares of the company's stock valued at $1,596,000 after purchasing an additional 18,992 shares during the last quarter. Finally, Y Intercept Hong Kong Ltd bought a new position in Option Care Health in the fourth quarter valued at approximately $327,000. 98.05% of the stock is owned by institutional investors and hedge funds.

Option Care Health Trading Up 2.2 %

Shares of OPCH opened at $32.90 on Monday. The stock has a 50 day simple moving average of $33.36 and a 200-day simple moving average of $28.76. The company has a current ratio of 1.73, a quick ratio of 1.32 and a debt-to-equity ratio of 0.77. The stock has a market cap of $5.40 billion, a PE ratio of 27.65, a PEG ratio of 2.30 and a beta of 1.07. Option Care Health has a 1 year low of $21.39 and a 1 year high of $35.53.

About Option Care Health

Option Care Health, Inc offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn's disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.